Clinical characteristics at baseline of the cohort and comparison according to the cell lineage
| Variable . | Whole cohort (n = 170) . | T-LGL (n = 120) . | CLPD-NKs (n = 50) . | P . |
|---|---|---|---|---|
| Age | .74 | |||
| Median, y | 64 | 65 | 61 | |
| Range, y | 20-90 | 20-87 | 27-90 | |
| Sex, no. (%) | .9 | |||
| Male | 55 (94) | 55 (66) | 56 (28) | |
| Female | 45 (86) | 45 (54) | 44 (22) | |
| Symptoms at diagnosis, no. (%) | 53 (90) | 53 (63) | 54 (27) | .8 |
| Neutropenia, no. (%)* | 62 (105) | 64 (75) | 60 (30) | .7 |
| Lymphocytosis, no. (%)† | 54 (92) | 50 (60) | 64 (32) | .07 |
| Anemia, no. (%)‡ | 30 (52) | 31 (37) | 30 (15) | .9 |
| Thrombocytopenia, no. (%)§ | 14 (24) | 13 (16) | 16 (8) | .7 |
| LGL count in PB, × 109/L | .5 | |||
| Median | 3.4 | 3.1 | 3.7 | |
| Range | 0.2-22 | 0.3-22 | 0.9-13 | |
| Splenomegaly, no. (%) | 21 (37) | 25 (31) | 21 (6) | .4 |
| Presence of MGUS, no. (%) | 21 (36) | 22 (26) | 20 (10) | .9 |
| Associated autoimmune disease | ||||
| RA, no. (%) | 10 (17) | 11 (14) | 6 (3) | .10 |
| AIHA, no. (%) | 7 (12) | 5 (6) | 12 (6) | .15 |
| Associated BM disorder | ||||
| MDS, no. (%) | 5 (9) | 6 (7) | 4 (2) | .25 |
| PRCA, no. (%) | 5 (8) | 6 (7) | 2 (1) | .15 |
| Presence of B-cell malignancy, no. (%) | 9 (15) | 10 (12) | 6 (3) | .3 |
| Treatment lines | .3 | |||
| Median | 1.5 | 1.7 | 1.2 | |
| Patients with somatic mutation in STAT3-SH2 domain, no. (%) | 28 (48) | 27 (33) | 30 (15) | .6 |
| Variable . | Whole cohort (n = 170) . | T-LGL (n = 120) . | CLPD-NKs (n = 50) . | P . |
|---|---|---|---|---|
| Age | .74 | |||
| Median, y | 64 | 65 | 61 | |
| Range, y | 20-90 | 20-87 | 27-90 | |
| Sex, no. (%) | .9 | |||
| Male | 55 (94) | 55 (66) | 56 (28) | |
| Female | 45 (86) | 45 (54) | 44 (22) | |
| Symptoms at diagnosis, no. (%) | 53 (90) | 53 (63) | 54 (27) | .8 |
| Neutropenia, no. (%)* | 62 (105) | 64 (75) | 60 (30) | .7 |
| Lymphocytosis, no. (%)† | 54 (92) | 50 (60) | 64 (32) | .07 |
| Anemia, no. (%)‡ | 30 (52) | 31 (37) | 30 (15) | .9 |
| Thrombocytopenia, no. (%)§ | 14 (24) | 13 (16) | 16 (8) | .7 |
| LGL count in PB, × 109/L | .5 | |||
| Median | 3.4 | 3.1 | 3.7 | |
| Range | 0.2-22 | 0.3-22 | 0.9-13 | |
| Splenomegaly, no. (%) | 21 (37) | 25 (31) | 21 (6) | .4 |
| Presence of MGUS, no. (%) | 21 (36) | 22 (26) | 20 (10) | .9 |
| Associated autoimmune disease | ||||
| RA, no. (%) | 10 (17) | 11 (14) | 6 (3) | .10 |
| AIHA, no. (%) | 7 (12) | 5 (6) | 12 (6) | .15 |
| Associated BM disorder | ||||
| MDS, no. (%) | 5 (9) | 6 (7) | 4 (2) | .25 |
| PRCA, no. (%) | 5 (8) | 6 (7) | 2 (1) | .15 |
| Presence of B-cell malignancy, no. (%) | 9 (15) | 10 (12) | 6 (3) | .3 |
| Treatment lines | .3 | |||
| Median | 1.5 | 1.7 | 1.2 | |
| Patients with somatic mutation in STAT3-SH2 domain, no. (%) | 28 (48) | 27 (33) | 30 (15) | .6 |
PB indicates peripheral blood; MGUS, monoclonal gammopathy of undetermined significance; MDS, myelodysplastic syndrome; STAT3, signal transducer and activator of transcription 3; and SH2, Src homology 2 domain.
Absolute neutrophil count ≤ 1.5 × 109/L.
Absolute lymphocyte count ≥ 4 × 109/L.
Hemoglobin ≤ 10 g/dL.
Platelet count ≤ 100 × 109/L.